Safety and Efficacy of Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Annals of Internal Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19
Ann. Intern. Med 2023 Apr 18;[EPub Ahead of Print], TH Evering, KW Chew, MJ Giganti, C Moser, M Pinilla, DA Wohl, JS Currier, JJ Eron, AC Javan, R Bender Ignacio, D Margolis, Q Zhu, J Ma, L Zhong, L Yan, U D'Andrea Nores, K Hoover, B Mocherla, MC Choudhary, R Deo, J Ritz, WA Fischer, CV Fletcher, JZ Li, MD Hughes, D Smith, ES DaarFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.